Optos and Toku Announce Agreement to Bring BioAge to Ultra-Widefield Retinal Imaging Devices

Collaboration brings AI-powered systemic health insights to more than 20,000 U.S. eye care practices using Optos ultra-widefield imaging devices.

Dunfermline, UK and San Diego, CA – September 16, 2025 – Optos, a division of Nikon Co. Ltd, Japan and global leader in ultra-widefield (UWF™) retinal imaging, and Toku, a pioneer in AI-powered health insights, announce an agreement that will make Toku’s BioAge available to users of Optos Daytona, Monaco, MonacoPro, and California devices in the United States.

Toku’s BioAge is an advanced AI solution that estimates a person’s biological age, a measure of overall health, by analyzing vascular and metabolic indicators visible in the retina. With a single pair of ultra-widefield retinal images, eye care providers can offer patients valuable information that extends beyond ocular health and provides insights into systemic wellness.

This collaboration reflects the Optos commitment to support its customers throughout the entire lifecycle of their devices. By integrating BioAge, a leading AI solution, eye care professionals can expand their health and wellness insights without the need to replace existing hardware.

“We are delighted to offer our customers the ability to seamlessly integrate BioAge into their workflow. This collaboration allows eye care professionals to deliver greater value to their patients through a deeper understanding of their overall wellness,” said Masayuki Numako, Director & Executive Vice President, Head of Healthcare Business Division.

“At Toku, our mission is to empower individuals with health insights that encourage proactive care and healthier lifestyles,” said Ehsan Vaghefi, CEO, Toku. “Through this agreement with Optos, we are excited to make BioAge accessible to more than 20,000 eyecare practices across the United States equipped with ultra-widefield imaging devices. Together, we are combining the power of AI and retinal photography to help patients take charge of their overall wellness.”

The integrated BioAge solution will be available for demonstration at Vision Expo West in Las Vegas, NV from September 17–20 at Optos booth F9065, where attendees can experience how retinal imaging and AI are shaping the future of eye care and preventative health.

For more information about Optos, visit www.optos.com. For more information about Toku and BioAge, visit www.tokueyes.com. 

About Optos

For more than 30 years, Optos has been the exclusive provider of 200-degree single-shot ultra-widefield retinal imaging systems to eye care professionals worldwide. With over 27,000 devices in use and supported by more than 3,000 clinical papers, Optos has also developed integrated ultra-widefield retinal imaging with optomap-guided Optical Coherence Tomography (OCT). Optos devices facilitate the early detection, management, and effective treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy, and age-related macular degeneration. Optos continues to lead the way in retinal imaging technology, setting the standard for excellence and innovation in eye care.

About Toku, Inc.

Toku, Inc., based in San Diego, CA, is a cutting-edge technology company that specializes in converting routine eye exams to comprehensive health assessments by developing AI-powered tools. The company’s first commercialized product, BioAge, uses AI to analyze biometric markers in the retina to accurately identify an individual’s biological age. Toku’s second product, CLAiR, provides cardiovascular risk assessment and has received Breakthrough Device designation from the United States Food and Drug Administration; however, it is not yet approved for use in the U.S. Toku is committed to making its technology widely accessible through major partnerships across the world. Toku’s Series A financing was co-led by National Vision, Inc., one of the largest optical retailers in the United States, and Topcon Healthcare, a leading provider of medical devices and intelligent software solutions for the global eye care community.

Disclaimer: BioAge is intended for general wellness use and is not approved or cleared by the U.S. Food and Drug Administration as a medical device.

OPTOS Media Contact:
Cassy Dump
Shine Communications for Optos
Cassy@heyshine.com
(619) 971-1887

Toku Media Contact:
Francesca Logan
Chief Commercial Officer
francesca.logan@tokueyes.com